Role of controlled septal infarct in hypertrophic obstructive cardiomyopathy

Cardiology in Review

Volumn 10, Issue 2, 2002, Pages 108-118

  Nielsen, Christopher D ^a   Spencer III, William H ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alcohol septal ablation; Asymmetric septal hypertrophy; Hypertrophic cardiomyopathy; Myomectomy; Nonsurgical septal reduction therapy; Outflow tract obstruction; Pacemaker

Indexed keywords

ALCOHOL;

ADULT; AGED; ALCOHOL SEPTAL ABLATION; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL HEART PACEMAKER; CATHETER ABLATION; CLINICAL ARTICLE; COMPLETE HEART BLOCK; FOLLOW UP; HEART FUNCTION; HEART HYPERTROPHY; HEART OUTFLOW TRACT OBSTRUCTION; HEART PACING; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MYOMECTOMY; SUDDEN DEATH; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0036129791     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200203000-00009     Document Type: Article

References (30)

1. The management of hypertrophic cardiomyopathy
2. Recent advances in the molecular genetics of hypertrophic cardiomyopathy
3. The inheritance of hypertrophic cardiomyopathy
4. Hypertrophic cardiomyopathy: Clinical spectrum and treatment
5. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy
6. Effects of propranolol on myocardial oxygen consumption, substrate extraction, and hemodynamics in hypertrophic obstructive cardiomyopathy
7. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy
8. Muscular subaortic stenosis: Hemodynamic and clinical improvement after disopyramide
9. Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy
10. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy
11. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blinded, crossover study (M-PATHY)
12. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy
13. Operative treatment in hypertrophic subaortic stenosis: Techniques, and the results of pre and post-operative assessments in 83 patients
14. Long-term results of left ventricular myotomy and myomectomy for obstructive hypertrophic cardiomyopathy
15. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy
16. Management of symptomatic hypertrophic obstructive cardiomyopathy: Long-term results after surgical therapy
17. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy
18. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients
19. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: Long-term follow-up of the first series of 25 patients
20. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy
21. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up
22. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic obstructive cardiomyopathy
23. Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring
24. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: Results in 50 consecutive patients
25. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy
26. Electrocardiographic changes after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
27. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
28. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy
29. Decreased expression of tumor necrosis factor alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy
30. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy